Urokinase Receptor mRNA Stability Involves Tyrosine Phosphorylation in Lung Epithelial Cells

American Journal of Respiratory Cell and Molecular Biology

Volumn 30, Issue 1, 2004, Pages 69-75

  Shetty, Sreerama ^a,b   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERBIMYCIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TYROSINE; UROKINASE RECEPTOR;

ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG TUMOR; PATHOGENESIS; PNEUMONIA; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

BENZOQUINONES; CELL LINE; DOWN-REGULATION; EPITHELIAL CELLS; HUMANS; LACTAMS, MACROCYCLIC; LUNG; PHOSPHORYLATION; QUINONES; RECEPTORS, CELL SURFACE; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TRANSFORMING GROWTH FACTOR BETA; TYROSINE;

EID: 0345742498     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2002-0305OC     Document Type: Article

References (44)

1. Mazar, A. P., J. Henkin, and R. H. Goldfarb. 1999. The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 3:15-32.
2. Dvorak, H. F. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-1659.
3. Dvorak, H. F., D. R. Senger, and A. M. Dvorak. 1983. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2:41-73.
4. Vassalli, J. D., A. P. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1067-1072.
5. Dano, K., P. A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L. S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:139-266.
6. Liotta, L. A., W. G. Stetler-Stevenson, and P. S. Steeg. 1991. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest. 9:543-551.
7. Mignatti, P., and D. B. Rifkin. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:161-195.
8. Idell, S. 1994. Extravascular coagulation and fibrin deposition in acute lung injury. New Horizons 2:566-574.
9. Idell, S. 1995. Coagulation, Fibrinolysis and Fibrin Deposition in Lung Injury and Repair. In Phan S. H., and R. S. Thrall, editors. Lung Biology in Health and Disease-Pulmonary Fibrosis. Marcel Dekker, New York. 743-776.
10. Chapman, H. A., P. Bertozzi, and J. J. Reilly. 1988. Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest 93:1256-1263.
11. Pedersen, H., N. Brunner, D. Francis, K. Osterlind, E. Ronne, H. H. Hansen, K. Dano, and J. Grondahl-Hansen. 1994. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54:4671-4675.
12. Pedersen, H., J. Grondahl-Hansen, D. Francis, K. Osterlind, H. H. Hansen, K. Dano, and N. Brunner. 1994. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res. 54:120-123.
13. Blasi, F., J. D. Vassalli, and K. Dano. 1987. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104:801-804.
14. Lund, L. R., V. Ellis, E. Ronne, C. Pyke, and K. Dano. 1995. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem. J. 310:345-352.
15. Lund, L. R., E. Ronne, A. L. Roldan, N. Behrendt, J. Romer, F. Blasi, and K. Dano. 1991. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells. J. Biol. Chem. 266:5177-5181.
16. Shetty, S., A. Kumar, and S. Idell. 1997. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol. Cell. Biol. 17:1075-1083.
17. Wang, Y., C. J. Jones, J. Dang, X. Liang, J. E. Olsen, and W. F. Doe. 1994. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 353:138-142.
18. Wang, G. J., M. Collinge, F. Blasi, R. Pardi, and J. R. Bender. 1998. Posttranscriptional regulation of urokinase plasminogen activator receptor messenger RNA levels by leukocyte integrin engagement. Proc. Natl. Acad. Sci. USA 95:6296-6301.
19. Pepper, M. S., K. Matsumoto, T. Nakamura, L. Orci, and R. Montesano. 1992. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J. Biol. Chem. 267:20493-20496.
20. Sprengers, E. D., and C. Kluft. 1987. Plasminogen activator inhibitors. Blood 69:381-387.
21. Idell, S., A. Kumar, C. Zwieb, D. Holiday, K. B. Koenig, and A. R. Johnson. 1994. Effects of TGF-beta and TNF-alpha on procoagulant and fibrinolytic pathways of human tracheal epithelial cells. Am. J. Physiol. 267: L693-L703.
22. Shetty, S., and S. Idell. 2000. Post-transcriptional regulation of urokinase mRNA. Identification of a novel urokinase mRNA-binding protein in human lung epithelial cells in vitro. J. Biol. Chem. 275:13771-13779.
23. Shetty, S., and S. Idell. 2000. Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro. Am. J. Physiol. (Lung Cell. Mol. Physiol.) 278:L148-L156.
24. Shetty, S., and S. Idell. 1999. Pottranscriptional regulation of urokinase receptor gene expression in lung carcinoma and malignant mesothelioma cells in vitro. Mol. Cell. Biochem. 199:189-200.
25. Shetty, S., and S. Idell. 1998. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Arch. Biochem. Biophys. 356:265-279.
26. Shetty, S., and S. Idell. 1998. A urokinase receptor mRNA binding protein from rabbit lung fibroblasts and mesothelial cells. Am. J. Physiol. 274: L871-L882.
27. Chapman, H. A. 1997. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9:714-724.
28. Ghiso, J. A. A., D. F. Alonso, E. F. Farias, D. E. Gomez, and E. Bal de Kier Joffe. 1999. Deregulation of the signaling pathways controlling urokinase production: its relationship with the invasive phenotype. Eur. J. Biochem. 263:295-304.
29. Shetty, S., A. Kumar, A. Johnson, and S. Idell. 1995. Regulation of Mesothelial Cell Mitogenesis by Antisense Oligonucleotides by Antisense Oligonucleotides for the Urokinase Receptor. Antisense Res. Dev. 5:307-314.
30. Shetty, S., A. Kumar, A. Johnson, S. Pueblitz, and S. Idell. 1995. Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am. J. Physiol. 268:L972-L982.
31. Waltz, D. A., L. Z. Sailor, and H. A. Chapman. 1993. Cytokines induce urokinase-dependent adhesion of human myeloid cells. J. Clin. Invest. 91:1541-1552.
32. Bhat, G. J., J. J. Gunaje, and S. Idell. 1998. Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells. Am. J. Physiol. 277:L301-L309.
33. Xing, R. H., A. Mazar, J. Henkin, and S. A. Rabbani. 1997. Prevention of breast cancer growth, invasion, and mrtastasis by anti-estrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 57: 3585-3593.
34. Achbarou, A., S. Kaiser, G. Tremblay, L. G. Ste-Marie, P. Brodt, D. Goltzman, and S. A. Rabbani. 1994. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res. 54:2372-2377.
35. Schmitt, M., N. Harbeck, C. Thomssen, O. Wilhelm, V. Magdolen, U. Reuning, K. Ulm, H. Hofler, F. Janicke, and H. Graeff. 1997. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78:285-296.
36. Hollas, W., N. Hoosein, L. W. Chung, A. Mazar, J. Henkin, K. Kariko, E. S. Barnathan, and D. Boyd. 1992. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemost. 68:662-666.
37. Mitsubayashi, S., T. Akiyama, T. Kurita, K. Okada, H. Bando, T. Sakai, and O. Matsuo. 1987. Plasminogen activator in bladder tumors. Urol. Res. 15:335-339.
38. Boyd, D., G. Florent, P. Kim, and M. Brattain. 1988. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 48:3112-3116.
39. Janicke, F., M. Schmitt, and H. Graeff. 1991. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost. 17:303-312.
40. Shetty, S., and S. Idell. 2001. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J. Biol. Chem. 276:24549-24556.
41. Montero, L., and Y. Nagamine. 1999. Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich element-mediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion. Cancer Res. 59:5286-5293.
42. Huang, S., L. New, Z. Pan, J. Han, and G. R. Nemerow. 2000. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J. Biol. Chem. 275:12266-12272.
43. Simon, C., H. Goepfert, and D. Boyd. 1998. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 58:1135-1139.
44. Kontoyiannis, D., M. Pasparakis, T. T. Pizarro, F. Cominelli, and G. Kollias. 1999. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10:387-398.